Musk says TSMC won't run Terafab AI chip complex

Vip Play amended convertible note purchase agreements with Rick Hackel, The Access Fund I, LP, extending maturity dates. Hackel notes totaling $300,000 now mature Feb. 28, 2027; Access note of $150,000 now matures Aug. 31, 2027. Notes carry 12% annual interest; principal and accrued interest due in a single balloon payment unless converted to common stock. Changes take effect Sept. 1, 2026; amendments or waivers now require only the company and the relevant noteholder. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vip Play Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046094), on October 07, 2026, and is solely responsible for the information contained therein.

1019 ET - MTY Food Group faces persistent macroeconomic headwinds and high uncertainty driven by intense quick-service restaurant competition. RBC's Ryland Conrad says in a report that uncertainty hinges around the scope, probability, timing and valuation of any potential transaction around MTY's ongoing strategic review, now in its tenth month. While an outcome could act as a catalyst for the stock, "sustained macro and competitive headwinds to limit any meaningful improvement in the near term." As a result, Conrad says the "focus remains on MTY's organic growth trajectory" where management continues improving and strengthening its network. The company is expected to report its 3Q results on Oct. 9. (adriano.marchese@wsj.com) (END) Dow Jones Newswires October 07, 2026 10:19 ET (14:19 GMT)

October 7 - Worthington Steel (WS.N) shares fell 8.8%, closing at $24.93. WS reported (link) adjusted earnings per share of $0.57 for the first quarter, below analysts’ expectations of $0.68, according to data compiled by LSEG. The company reported quarterly revenue of $953.9 million, exceeding analysts’ estimates of $885.9 million, mainly due to the acquisition of Kloeckner. The company stated that the sale of Kloeckner Disposal Group is expected to be completed within one year after the acquisition. Of the two brokerages covering the stock, one rates it “Buy” and the other “Hold”; the median price target is $46. Including the day’s movement, WS shares are up 1.4% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translations may contain errors or fail to capture the intended context; Reuters does not guarantee their accuracy and provides them purely for reader convenience. Reuters assumes no liability for any loss or damage arising from the use of these automated translation features.)

October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)